bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
October 12 2022 - 8:15AM
Business Wire
Powerful platform reveals the lung
environment for diagnosing lung diseases
bioAffinity Technologies, Inc., (NASDAQ: BIAF; BIAFW) will
present results of its research into the use of flow cytometry for
analyzing the lung environment to detect diseases of the lung at
the American College of Chest Physicians (CHEST) 2022 conference
Oct. 16-19, 2022.
The presentation, Sputum Analysis By Flow Cytometry To Assess
Lung Health, will be part of the Lung Cancer Assessment and Risk
Calculations session on Oct. 19 beginning at 11:15 a.m. (ET).
bioAffinity Research Scientist Lydia Bederka, PhD, will present
data showing how flow cytometry can identify reproducible cell
populations from whole sputum samples that can be used in the
development of diagnostics for COPD and asthma, and has been used
to develop bioAffinity’s initial product, CyPath® Lung, that
detects early-stage lung cancer.
CyPath® Lung is a non-invasive test that has shown 92%
sensitivity and 87% specificity in detecting early-stage lung
cancer in individuals at high risk for the disease who have lung
nodules less than 20mm. The test is marketed by Precision Pathology
Services in San Antonio, Texas.
“Flow cytometry can provide the foundation for impactful lung
diagnostic tests,” said bioAffinity’s Chief Science and Medical
Officer Vivienne Rebel, MD, PhD. “With recent improvements in
antibody panels, fluorochromes and methods of detecting fluorescent
signals, flow cytometry allows for rapid analysis of large numbers
of sputum-derived cells. Automation of flow analysis, which we have
achieved with our test for lung cancer, alleviates the potential
bias problem. A flow cytometry platform can therefore provide
insights into lung health, similar to the way flow cytometry gives
insights into hematopoietic health and diseases by analyzing blood
and bone marrow.”
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage
lung cancer. CyPath® Lung is marketed as a Laboratory Developed
Test (LDT) by Precision Pathology Services. OncoSelect®
Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is
advancing its discoveries shown in vitro to kill cancer cells
without harm to normal cells. Research and optimization of the
Company’s platform technologies are conducted in its laboratories
at The University of Texas at San Antonio.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221012005471/en/
Company Contact: Maria Zannes, President & Chief
Executive Officer mz@bioaffinitytech.com
Investor Relations Contact: Tiberend Strategic Advisors,
Inc. Jonathan Nugent jnugent@tiberend.com or David Irish
dirish@tiberend.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024